Belpointe Asset Management LLC Alaunos Therapeutics, Inc. Transaction History

Belpointe Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Mar 06, 2019	SELL	$1.61 - $3.62 $132,020 - $296,840	-82,000 Closed	0 $0
Q3 2018 Nov 23, 2018	BUY	$2.26 - $3.27 $185,319 - $268,140	82,000 New	82,000 $262,000
Q1 2018 Aug 06, 2018	SELL	$3.46 - $5.14 $283,720 - $421,480	-82,000 Closed	0 $0
Q4 2017 Feb 15, 2018	SELL	$4.0 - $6.54 $158,140 - $258,558	-39,535 Reduced 32.53%	82,000 $339,000
Q3 2017 Nov 16, 2017	BUY	$4.99 - $6.57 $606,459 - $798,484	121,535	121,535 $746,000

106K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $136M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Belpointe Asset Management LLC with notifications on news.